SCHEMBL7740796

SCHEMBL7740796

CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NCc1ccc2ccccc2n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 10/20 0.81
ABCB1 P08183 3/20 0.81
ABCC4 O15439 2/20 0.81
ABCB11 O95342 2/20 0.81
TACR2 P21452 2/20 0.81
TBXAS1 P24557 2/20 0.81
OPRM1 P35372 2/20 0.81
OPRD1 P41143 2/20 0.81
OPRK1 P41145 2/20 0.81
SLC6A3 Q01959 2/20 0.81
KCNH2 Q12809 2/20 0.81
ABCG2 Q9UNQ0 2/20 0.81
ABCC3 O15438 1/20 0.81
CACNA1F O60840 1/20 0.81
HTR1A P08908 1/20 0.81
DRD2 P14416 1/20 0.81
DRD3 P35462 1/20 0.81
AVPR1A P37288 1/20 0.81
HTR2B P41595 1/20 0.81
CACNA1D Q01668 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27557880 1.00 CYP3A4 (0.81) CYP3A4ABCB1ABCC4ABCB11TACR2
SCHEMBL9953067 0.90 CYP3A4 (0.65) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL8584252 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL13953012 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL1976548 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL8584255 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL20451344 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL6881 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL21683360 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2
Saquinavir SCHEMBL1176566 0.89 CYP3A4 (1.00) CYP3A4ABCB1ABCC4ABCB11TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed
US-20080161324-A1 Compositions and methods for treatment of viral diseases EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) 2008-07-03 US disclosed
US-20080161324-A1 Compositions and methods for treatment of viral diseases EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) 2008-07-03 US disclosed
WO-2008033466-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PRE. LTD. (SG) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES HTR1A, HTR3B, HTR3A CYP3A4 403/4885ABCB1 713/4885ABCC4 1290/4885
US-20080161324-A1 Compositions and methods for treatment of viral diseases HAVCR2, EIF2AK2, RNASE1 CYP3A4 1342/4885ABCB1 1291/4885ABCC4 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.